Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · Real-Time Price · USD

7.40

-0.17 (-2.25%)

At close: Jan 9, 2026, 4:00 PM EST

7.38

-0.02 (-0.27%)

After-hours: Jan 9, 2026, 7:05 PM EST

Gyre Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 9, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	673	1,038	1,967	-
Market Cap Growth	-35.76%	-47.22%	-	-
Enterprise Value	614	1,050	1,946	-
Last Close Price	7.40	12.10	25.69	-
PE Ratio	189.06	85.93	-	-
PS Ratio	6.03	9.82	17.34	-
PB Ratio	6.60	10.55	25.07	-
P/TBV Ratio	6.93	16.85	-	-
P/FCF Ratio	232.25	-	113.23	-
P/OCF Ratio	173.48	-	75.99	-
EV/Sales Ratio	5.72	9.93	17.15	-
EV/EBITDA Ratio	42.74	58.96	95.72	-
EV/EBIT Ratio	51.00	64.73	101.27	-
EV/FCF Ratio	211.91	-	111.99	-
Debt / Equity Ratio	0.01	0.02	0.01	0.01
Debt / EBITDA Ratio	0.08	0.09	0.02	0.06
Debt / FCF Ratio	0.40	-	0.02	0.11
Asset Turnover	0.75	0.87	1.13	-
Inventory Turnover	0.64	0.73	0.89	-
Quick Ratio	5.41	2.64	2.49	3.33
Current Ratio	6.20	3.32	2.85	4.06
Return on Equity (ROE)	10.02%	20.24%	-113.45%	-
Return on Assets (ROA)	5.29%	8.38%	11.93%	-
Return on Capital (ROIC)	6.30%	11.34%	15.83%	-
Return on Capital Employed (ROCE)	8.40%	15.30%	19.90%	12.70%
Earnings Yield	0.99%	1.16%	-4.72%	-
FCF Yield	0.43%	-0.57%	0.88%	-
Buyback Yield / Dilution	-24.46%	-55.39%	13.02%	-

Updated Nov 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q